patent.fyi
Applications  /  US 2026/0356832
United States Patent Application Publication

US 2026/0356832 A1

Published
Nov 12, 2026
Filed
Sep 19, 2023
Earliest date on the face
Sep 20, 2022
Classification
C07D 471/04
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.6Exocyclic methylene at X3

What ifWhat if the ring carbon at X3 forms an exocyclic double bond to a methylene carbon?
Claim language“O, S, and N(R8)”

A carbonyl methylenation converts a ketone at X3 to a terminal alkene. The exocyclic double bond keeps X3 trigonal planar and presents a nonpolar methylene group to the binding surface.

1.7Four-membered ring at X2–X3

What ifWhat if X2 and X3 are adjacent carbons that share an edge with a four-membered ring?
Claim language“5- to 7-membered ring”

A photochemical [2+2] cycloaddition joins ethylene across an X2–X3 alkene. The resulting cyclobutane fixes the relative geometry of the two junction carbons.

1.8One-carbon spiro ring junction

What ifWhat if a cyclopentane shares a single saturated carbon with the core?
Claim language“R5 groups on two adjacent carbon atoms”

Two carbon–carbon bonds from the same core carbon connect to opposite ends of a four-carbon chain. The five-membered ring and core share one tetrahedral carbon, which directs the cyclopentane out of the core ring plane.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Component substitution

Sulfone linker in a matched pair

A sulfone group, —S(O)₂—, replaces the thioether linker between the fused heterocyclic core and R2. The sulfone connects the same two attachment atoms through sulfur, and both compounds retain the same core substituents and R2 ring. A purified ubiquitin-specific protease assay measures concentration–response curves for the pair under identical enzyme and substrate conditions.

Thione substitution at the fused core

A thiocarbonyl group, C═S, replaces C═O at X3 in a matched pair of fused heterocycles. Both structures retain the same ring bonds at X3, the same linker, and the same peripheral substituents. The assay measures initial substrate cleavage rates across a concentration series for each compound and uses compound-only wells to measure fluorescence background.

Parameter or scale variation

Three carbon linker lengths

A matched series connects the same fused heterocyclic core and R2 ring through one, two, or three consecutive methylene groups. Each series member has hydrogen at both substituent positions on every linker carbon and retains the same attachment atoms on the core and R2 ring. An eight-point concentration series with threefold dilution measures how linker length affects inhibition of the same ubiquitin-specific protease under fixed assay conditions.

Combination with existing systems

Binding measurements by surface plasmon resonance

A surface plasmon resonance flow cell carries an immobilized ubiquitin-specific protease on a sensor surface and a protein-free reference surface in a parallel channel. A concentration series of the fused heterocycle flows across both channels in matched buffer and solvent, followed by buffer alone to record dissociation. The reference-subtracted response at each concentration provides an equilibrium binding curve for estimating affinity.

Automated or data-driven variant

Automated selection of matched structures

A structure enumeration program accepts an atom-mapped fused heterocycle and a table of allowed atom and substituent changes. It generates one change per structure, checks valence and aromaticity, applies the restriction on the X1 nitrogen and X3 NH pairing, and removes duplicate structures. The program joins the resulting structures to measured protease inhibition values and reports matched pairs with their activity differences.

Specific version of a part

Phosphorus at the ring position

Phosphorus forms a single bond to each neighboring ring atom and to a methyl group. The phosphoryl oxygen provides a hydrogen-bond acceptor at the ring junction region.

Acetylene bridge to R2

Palladium-catalyzed coupling joins a halogenated aromatic core to a terminal ethynyl derivative of R2. The two sp-hybridized carbons hold the attachment vectors along the same axis.

Branched acyclic terminal group

The linker bonds to the central carbon of the tert-butyl group. The three methyl branches provide a compact nonpolar surface for contact with a hydrophobic pocket.

One nitrogen at X5

X5 is a pyridine-like nitrogen, and X4, X6, and X7 are carbon atoms bearing hydrogen. The X5 lone pair lies in the ring plane and serves as a hydrogen-bond acceptor.

Nitrile at an R5 position

R5 is a nitrile attached through its carbon to a core ring carbon. The linear C≡N group places the terminal nitrogen along the axis of the attachment bond.

Hydroxylated ethyl side chain

R1 is a 2-hydroxyethyl group attached through its first carbon. The two-carbon chain places a primary alcohol at the end of two rotatable carbon–carbon bonds.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 8,809,532 B2
Published
Aug 19, 2014
Filed
Dec 14, 2010
Class
C07D 471/04
Document BUS 11,136,324 B2
Published
Oct 5, 2021
Filed
Mar 2, 2018
Class
C07D 487/04
Claim 1
Document A
Document B
1.1C(R1) and N
The six-membered ring contains three double bonds and one, two, three or four nitrogen atoms.
A · US 8,809,532 B2 · ¶ 63
1.2X3 is selected from the group consisting of C(R1)2, C(═Z), N(R7), S, and O
1.3X4, X5, X6, and X7 are each independently selected from the group consisting of C(R5) and N
M1, M2, M3 and M4 are each independently selected from the group consisting of N and —CR6;
B · US 11,136,324 B2 · ¶ 11
1.4each R1 and R5 is independently selected from the group consisting of hydrogen, deuterium, halogen, —CN, —OH, —SH, —COOH, —NH2, —NHC1-12 alkyl, —N(C1-12 alkyl)2, C1-12 alkyl, C1-12 deuterated alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, C1-12 deuterated alkoxy, C1-12 alkylthio, —COC1-12 alkyl, —OC(O)C1-12 alkyl, —C(O)OC1-12 alkyl, —OC(O)OC1-12 alkyl, —SO2C1-12 alkyl, —NHSO2C1-12 alkyl, —N(C1-12 alkyl)SO2C1-12 alkyl, —SO2NH2, —SO2NHC1-12 alkyl, —SO2N(C1-12 alkyl)2, —CONH2, —CONHC1-12 alkyl, —CON(C1-12 alkyl)2, —NHCOC1-12 alkyl, —N(C1-12 alkyl)COC1-12 alkyl, C3-12 cycloalkyl, C3-12 cycloalkenyl, C6-10 aryl, 5- to 10-membered heteroaryl, and 3- to 12-membered heterocyclyl
R5 is halogen, nitro, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, —(CH2)nC(O)R12, —(CH2)nC(O)NR12R13, —(CH2)nC(O)OR12, —(CH2)nNR12R13, —(CH2)nNR13C(O)R12, —(CH2)nNR13S(O)mR12, —(CH2)nOR12, —(CH2)nS(O)mR12, cycloalkyl, heterocyclyl, aryl, or heteroaryl; each R6 is independently hydrogen, deuterium, halogen, nitro, cyano, alkyl, deuterated alkyl, haloalkyl, —(CH2)nC(O)R9, —(CH2)nC(O)NR10R11, —(CH2)nC(O)OR9, —(CH2)nNR10R11, —(CH2)nNR10C(O)R9, —(CH2)nNR10S(O)mR9, —(C
B · US 11,136,324 B2 · claim 1
1.5wherein the —OH, —SH, —NH2, —NHC1-12 alkyl, —N(C1-12 alkyl)2, C1-12 alkyl, C1-12 deuterated alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, C1-12 deuterated alkoxy, C1-12 alkylthio, —COC1-12 alkyl, —OC(O)C1-12 alkyl, —C(O)OC1-12 alkyl, —OC(O)OC1-12 alkyl, —SO2C1-12 alkyl, —NHSO2C1-12 alkyl, —N(C1-12 alkyl)SO2C1-12 alkyl, —SO2NH2, —SO2NHC1-12 alkyl, —SO2N(C1-12 alkyl)2, —CONH2, —CONHC1-12 alkyl, —CON(C1-12 alkyl)2, —NHCOC1-12 alkyl, —N(C1-12 alkyl)COC1-12 alkyl, C3-12 cycloalkyl, C3-12 cycloalkenyl, C6-10 aryl, 5- to 10-membered heteroaryl, and 3- to 12-membered heterocyclyl are optionally independently substituted with one or more substituents
Y is —C(O)—; each Ra is independently halogen, nitro, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, —(CR9R10)n—, alkenyl, alkynyl, —(CH2)nC(O)R9, —(CH2)nC(O)NR10R11, —(CH2)nC(O)OR9, —(CH2)nNR10R11, —(CH2)nR10C(O)R9, —(CH2)nNR10S(O)mR9, —(CH2)nOR9, —(CH2)nS(O)mR9, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally and independently substituted by one or more sub
B · US 11,136,324 B2 · claim 1
1.6Z is selected from the group consisting of O, S, and N(R8)
1.7or X2 and X3 are linked to each other to form a 5- to 7-membered ring optionally substituted with one or more substituents
The bicyclic heterocycle is a monocyclic heterocycle fused to a phenyl group, or a monocyclic heterocycle fused to a monocyclic cycloalkyl, or a monocyclic heterocycle fused to a monocyclic cycloalkenyl, or a monocyclic heterocycle fused to a monocyclic heterocycle, or a bridged monocyclic heterocycle ring system in which two non adjacent atoms of the ring are linked by an alkylene bridge of 1, 2, 3, or 4 carbon atoms, or an alkenylene bridge of two, three, or four carbon ato
A · US 8,809,532 B2 · ¶ 62
1.8or R5 groups on two adjacent carbon atoms, together with the carbon atoms to which they are linked, form C5-7 cycloalkenyl, 5- to 7-membered heterocycloalkenyl, phenyl, or 5- to 6-membered heteroaryl optionally substituted with one or more substituents
The bicyclic heteroaryl consists of a monocyclic heteroaryl fused to a phenyl, or a monocyclic heteroaryl fused to a monocyclic cycloalkyl, or a monocyclic heteroaryl fused to a monocyclic cycloalkenyl, or a monocyclic heteroaryl fused to a monocyclic heteroaryl, or a monocyclic heteroaryl fused to a monocyclic heterocycle.
A · US 8,809,532 B2 · ¶ 63
or, any two Ra on ring B can form a new cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the newly formed cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally further substituted by one or more substituents selected from the group consisting of hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, halogen, amino, nitro, hydroxy, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —(CR9R10)n—, —(CH2)nOR9, —(CH2)nSR9, —(CH2)nC(O)R9, —(CH2)nC(
B · US 11,136,324 B2 · ¶ 42
1.9L is selected from the group consisting of —(C(R3R4))m—, —O—, —S—, —N(R9)—, —S(O)—, and —S(O)2
The compound according to claim 1 or a pharmaceutically acceptable salt thereof, selected from the group consisting of: 2-methyl-6-[(E)-2-(6-methylpyridin-3-yl)vinyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole; 2-methyl-6-[(6-methylpyridin-3-yl)ethynyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole; 2-methyl-6-(pyridin-3-ylethynyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole; 2-methyl-6-(pyridin-4-ylethynyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole; 6-[(E)-2-(6-methylpyridin-3-yl)v
A · US 8,809,532 B2 · claim 6
1.10R2 is selected from the group consisting of C3-12 cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl, 3- to 12-membered heterocyclyl, and C5-7 cycloalkenyl
ring A is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl are each optionally further substituted by one or more substituents selected from the group consisting of deuterium, alkyl, deuterated alkyl, halogen, amino, nitro, hydroxy, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —(CH2)nOR9, —(CH2)nSR9, —(CH2)nC(O)R9, —(CH2)nC(O)OR9, —(CH2)nS(O)mR9, —(CH2)nNR10R11, —(CH2)nC(O)NR10R11, —(CH2)nC(O)NHR10, —(CH2)n
B · US 11,136,324 B2 · ¶ 15
1.11wherein the C3-12 cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl, 3- to 12-membered heterocyclyl, and C5-7 cycloalkenyl are optionally independently substituted with one or more R2a
In one embodiment, Q is substituted or unsubstituted monocyclic aryl, substituted or unsubstituted bicyclic aryl, substituted or unsubstituted monocyclic heteroaryl, or substituted or unsubstituted bicyclic heteroaryl, wherein Q, when substituted, is independently substituted with 1, 2, 3, 4, or 5 substituents, wherein the substituent is halogen, cyano, C1-C5 haloalkyl, C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, hydroxy, C1-C5 alkoxy, —O—C1-C5 haloalkyl, —S—C1-C5 alkyl, —S—C1
A · US 8,809,532 B2 · ¶ 97
1.12each R3 and R4 is independently selected from the group consisting of hydrogen, deuterium, halogen, —CN, —OH, —SH, —COOH, —NH2, —NHC1-12 alkyl, —N(C1-12 alkyl)2, C1-12 alkyl, C1-12 deuterated alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, C1-12 deuterated alkoxy, C1-12 alkylthio, —COC1-12 alkyl, —OC(O)C1-12 alkyl, —C(O)OC1-12 alkyl, —OC(O)OC1-12 alkyl, —SO2C1-12 alkyl, —NHSO2C1-12 alkyl, —N(C1-12 alkyl)SO2C1-12 alkyl, —SO2NH2, —SO2NHC1-12 alkyl, —SO2N(C1-12 alkyl)2, —CONH2, —CONHC1-12 alkyl, —CON(C1-12 alkyl)2, —NHCOC1-12 alkyl, —N(C1-12 alkyl)COC1-12 alkyl, C3-12 cycloalkyl, C3-12 cycloalkenyl, C6-10 aryl, 5- to 10-membered heteroaryl, and 3- to 12-membered heterocyclyl wherein the —OH, —SH, —NH2, —NHC1-12 alkyl, —N(C1-12 alkyl)2, C1-12 alkyl, C1-12 deuterated alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, C1-12 deuterated alkoxy, C1-12 alkylthio, —COC1-12 alkyl, —OC(O)C1-12 alkyl, —C(O)OC1-12 alkyl, —OC(O)OC1-12 alkyl, —SO2C1-12 alkyl, —NHSO2C1-12 alkyl, —N(C1-12 alkyl)SO2C1-12 alkyl, —SO2NH2, —SO2NHC1-12 alkyl, —SO2N(C1-12 alkyl)2, —CONH2, —CONHC1-12 alkyl, —CON(C1-12 alkyl)2, —NHCOC1-12 alkyl, —N(C1-12 alkyl)COC1-12 alkyl, C3-12 cycloalkyl, C3-12 cycloalkenyl, C6-10 aryl, 5- to 10-membered heteroaryl, and 3- to 12-membered heterocyclyl are optionally independently substituted with one or more substituents or R3 and R4, together with the carbon atom to which they are linked, form C3-6 cycloalkyl or 3- to 6-membered heterocycloalkyl optionally substituted with one or more substituents R6 is selected from the group consisting of hydrogen, halogen, —CN, —OH, —SH, —COOH, —NH2, —NHC1-12 alkyl, —N(C1-12 alkyl)2, C1-12 alkyl, C1-12 deuterated alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, C1-12 deuterated alkoxy, C1-12 alkylthio, —COC1-12 alkyl, —OC(O)C1-12 alkyl, —C(O)OC1-12 alkyl, —OC(O)OC1-12 alkyl, —SO2C1-12 alkyl, —NHSO2C1-12 alkyl, —N(C1-12 alkyl)SO2C1-12 alkyl, —SO2NH2, —SO2NHC1-12 alkyl, —SO2N(C1-12 alkyl)2, —CONH2, —CONHC1-12 alkyl, —CON(C1-12 alkyl)2, —NHCOC1-12 alkyl, —N(C1-12 alkyl)COC1-12 alkyl, C3-12 cycloalkyl, C3-12 cycloalkenyl, C6-10 aryl, 5- to 10-membered heteroaryl, and 3- to 12-membered heterocyclyl wherein the —OH, —SH, —NH2, —NHC1-12 alkyl, —N(C1-12 alkyl)2, C1-12 alkyl, C1-12 deuterated alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, C1-12 deuterated alkoxy, C1-12 alkylthio, —COC1-12 alkyl, —OC(O)C1-12 alkyl, —C(O)OC1-12 alkyl, —OC(O)OC1-12 alkyl, —SO2C1-12 alkyl, —NHSO2C1-12 alkyl, —N(C1-12 alkyl)SO2C1-12 alkyl, —SO2NH2, —SO2NHC1-12 alkyl, —SO2N(C1-12 alkyl)2, —CONH2, —CONHC1-12 alkyl, —CON(C1-12 alkyl)2, —NHCOC1-12 alkyl, —N(C1-12 alkyl)COC1-12 alkyl, C3-12 cycloalkyl, C3-12 cycloalkenyl, C6-10 aryl, 5- to 10-membered heteroaryl, and 3- to 12-membered heterocyclyl are optionally independently substituted with one or more R6a each R7, R8, or R9 is independently selected from the group consisting of hydrogen, —NH2, C1-12 alkyl, C1-12 deuterated alkyl, C1-12 alkoxy, C1-12 deuterated alkoxy, C3-12 cycloalkyl, and 3-to 12-membered heterocyclyl wherein the —NH2, C1-12 alkyl, C1-12 deuterated alkyl, C1-12 alkoxy, C1-12 deuterated alkoxy, C3-12 cycloalkyl, or 3- to 12-membered heterocyclyl is optionally substituted with one or more substituents each R2a and R6a is independently selected from the group consisting of hydrogen, deuterium, halogen, —CN, —OH, —SH, —COOH, —NH2, —NHC1-12 alkyl, —N(C1-12 alkyl)2, C1-12 alkyl, C1-12 deuterated alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, C1-12 deuterated alkoxy, C1-12 alkylthio, —COC1-12 alkyl, —OC(O)C1-12 alkyl, —C(O)OC1-12 alkyl, —OC(O)OC1-12 alkyl, —SO2C1-12 alkyl, —NHSO2C1-12 alkyl, —N(C1-12 alkyl)SO2C1-12 alkyl, —SO2NH2, —SO2NHC1-12 alkyl, —SO2N(C1-12 alkyl)2, —CONH2, —CONHC1-12 alkyl, —CON(C1-12 alkyl)2, —NHCOC1-12 alkyl, —N(C1-12 alkyl)COC1-12 alkyl, C3-12 cycloalkyl, C3-12 cycloalkenyl, C6-10 aryl, 5- to 10-membered heteroaryl, and 3- to 12-membered heterocyclyl wherein the —OH, —SH, —NH2, —NHC1-12 alkyl, —N(C1-12 alkyl)2, C1-12 alkyl, C1-12 deuterated alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, C1-12 deuterated alkoxy, C1-12 alkylthio, —COC1-12 alkyl, —OC(O)C1-12 alkyl, —C(O)OC1-12 alkyl, —OC(O)OC1-12 alkyl, —SO2C1-12 alkyl, —NHSO2C1-12 alkyl, —N(C1-12 alkyl)SO2C1-12 alkyl, —SO2NH2, —SO2NHC1-12 alkyl, —SO2N(C1-12 alkyl)2, —CONH2, —CONHC1-12 alkyl, —CON(C1-12 alkyl)2, —NHCOC1-12 alkyl, —N(C1-12 alkyl)COC1-12 alkyl, C3-12 cycloalkyl, C3-12 cycloalkenyl, C6-10 aryl, 5- to 10-membered heteroaryl, and 3- to 12-membered heterocyclyl are optionally independently substituted with one or more substituents m is selected from the group consisting of 1, 2, and 3 provided that when X1 is N, X3 is not NH.
R3 is selected from the group consisting of C1-8 alkyl, C1-8 deuterated alkyl, C1-8 alkoxy, C1-8 haloalkoxy, C3-8 cycloalkyl and 3 to 10 membered heterocyclyl, wherein the C1-8 alkyl, C1-8 deuterated alkyl, C1-8 alkoxy, C1-8 haloalkoxy, C3-8 cycloalkyl and 3 to 10 membered heterocyclyl are each optionally further substituted by one or more substituents selected from the group consisting of hydrogen, deuterium, C1-8 alkyl, C1-8 deuterated alkyl, C1-8 haloalkyl, halogen, amino,
B · US 11,136,324 B2 · ¶ 77

An empty cell means only that no passage was reproduced there.

Statements in these documents
Treatment of dementias of various types, such as but not limited to, Alzheimer's disease (AD), Parkinson's disease, Huntington's disease and other forms, continue to be unmet medical needs.
A · US 8,809,532 B2 · ¶ 4
The present invention relates to indole and indoline derivatives, compositions comprising these indole and indoline derivatives, and methods of preventing or treating disease conditions such as neurodegeneration or neuropsychiatric disorders using such compounds and compositions.
A · US 8,809,532 B2 · ¶ 3
At present, there are no drugs approved for treating NASH.
B · US 11,136,324 B2 · ¶ 5
ASK1 inhibitors have great potential for the clinical treatment of NASH, and have potential valuable application in the treatment of other diseases including neurodegenerative diseases, cardiovascular diseases, inflammation, autoimmune metabolic diseases and the like.
B · US 11,136,324 B2 · ¶ 5
Cite aspatent.fyi, US 2026/0356832 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356832/, SHA-256 a54dd869db4573424843119a6951f663c36a8bb6e3dd73a361348eaa90f04f18
First published
Permanent addresshttps://patent.fyi/US20260356832/
Content fingerprint (SHA-256)a54dd869db4573424843119a6951f663c36a8bb6e3dd73a361348eaa90f04f18
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi